TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
To the Copenhagen Stock Exchange
Announcement No. 14-07 / Copenhagen, 1 May 2007
Proceedings at the extraordinary general meeting of TopoTarget A/S
On 30 April 2007, an extraordinary general meeting was held, as per the notice
convening the meeting dated 20 April 2007.
The Board of Directors' proposal to authorise the Board to increase the
company's share capital by up to a total of DKK 21,000,000 represented by
shares with a nominal value of DKK 1 each in the period until 1 May 2009 was
unanimously adopted.
The authorisation, which will be included as a new article 7a in the company's
articles of association, has been given in connection with the company's
acquisition of Apoxis SA and the financing of the consolidated activities of
Apoxis SA and the company until the end of 2009.
The Board of Directors' proposal to authorise the Board to increase the
company's share capital by up to a total of DKK 5,000,000 represented by shares
with a nominal value of DKK 1 each in the period until 1 May 2010 was
unanimously adopted.
This authorisation will be carried out by increasing the authorisation in
article 7 in the articles of association from nominally DKK 846,830 to
nominally DKK 5,000,000.
The changing of the company's share registrar from “Danske Bank” to “VP
Investor Services A/S (VP Services A/S)” was unanimously adopted. The article
8, section 1, in the articles of association will be changed accordingly.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Leif Hamø Telephone +45 39 17 83 45
Chief Financial Officer Mobile +45 40 33 40 83
Background information
About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company,
headquartered in Denmark and with subsidiaries in the UK, Germany and the USA,
dedicated to finding ''Answers for Cancer'' and developing improved cancer
therapies. TopoTarget is founded and run by clinical cancer specialists and
combines years of hands-on clinical experience with in-depth understanding of
the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer enzyme regula-tors (mainly HDAC, mTOR, and topoisomerase
II inhibitors) and a strong development foundation has been built. TopoTarget
has a broad portfolio of small molecule preclini-cal drug candidates and seven
drugs are in clinical development, including both novel anti-cancer
therapeutics and new cancer indications for existing drugs. Savene™ is
TopoTarget's first product on the market. In addition to organic growth,
TopoTarget consistently looks for opportunities to strengthen and expand its
activities through acquisitions and in-licensing. For more information, please
refer to www.topotarget.com.
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline includ-ing the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expecta-tions and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to,
the following: the risk that any one or more of the drug development programs
of TopoTarget will not proceed as planned for technical, scientific or
commercial reasons or due to patient enrolment issues or based on new
information from nonclinical or clinical studies or from other sources; the
success of competing products and technolo-gies; technological uncertainty and
product development risks; uncertainty of addi-tional funding; TopoTarget's
history of incurring losses and the uncertainty of achieving profitability;
TopoTarget's stage of development as a biopharmaceutical company; government
regulation; patent infringement claims against TopoTarget's products, processes
and technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
